Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point?
This editorial review takes an in-depth look to the effect of hemoglobin (Hb) normalization with erythropoietin on quality of life (QoL) in chronic kidney disease (CKD). The analysis of the current available data shows major inhomogeneities in the tools used for assessment of QoL and in data reporting. Furthermore, the major trials on Hb normalization were generally not primarily designed to analyze QoL as a specific end-point. However, current data suggest that only partial correction of anemia with EPO may improve QoL, whereas correction of Hb to above 12 g/dL does not exert any positive effect. Finally, the authors provide recommendations on a more rigorous assessment of QoL in future trials in CKD patients.
Covic
A
A
Nephrology Clinic, 'Dr. C. I. Parhon' University Hospital, Iasi - Romania. acovic@xnet.ro
Seica
A
A
Gusbeth-Tatomir
P
P
Goldsmith
D
D
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000523:psychology; D011788:Quality of Life; D016896:Treatment Outcome
D006454:Hemoglobins; D004921:Erythropoietin